A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20)

Current Medicinal Chemistry

Volumn 13, Issue 20, 2006, Pages 2369-2384

  Manfredi, Roberto ^a   Sabbatani, Sergio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiretroviral therapy; Efficacy; Enfuvirtide (T 20); Fusion inhibitors; Future perspectives; Indications; Pharmacokinetics; Randomized clinical trials; Safety

Indexed keywords

ABACAVIR; AMD 070; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; HEPARIN; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; T 1249; TENOFOVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ADJUVANT THERAPY; ANOREXIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BACTERIAL PNEUMONIA; BRONCHITIS; CHILL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COUGHING; DEPRESSION; DERMATITIS; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ECCHYMOSIS; EOSINOPHILIA; ERYTHEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; INJECTION SITE REACTION; KIDNEY DISEASE; LIPODYSTROPHY; LIVER DISEASE; LYMPHADENOPATHY; MALAISE; NAUSEA; NONHUMAN; OTITIS; PHARMACODYNAMICS; PHARMACOGENOMICS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; RIGOR; SALVAGE THERAPY; SCLERODERMA; SINGLE DRUG DOSE; SINUSITIS; SKIN CYST; SKIN FIBROSIS; SKIN INDURATION; SKIN NODULE; SKIN PAIN; SKIN PRURITUS; SUBCUTANEOUS NODULE; SYSTEMIC DISEASE; THRUSH; VIRUS INHIBITION; VIRUS RESISTANCE; VOMITING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DRUG TOXICITY; FORECASTING; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33746929059     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986706777935069     Document Type: Review

References (40)

1. Yeni, P.G.; Hammer, S.M.; Hirsch, M.S.; Saag, M.S.; Schechter, M.; Carpenter, C.C.; Fischl, M.A.; Gatell, J.M.; Gazzard, B.G.; Jacobsen, D.M.; Katzenstein, D.A.; Montaner, J.S.; Richman, D.D.; Schooley, R.T.; Thompson, M.A.; Vella, S.; Volberding, P.A. JAMA, 2004, 292, 251.
2. Sharland, M.; Blanche, S.; Castelli, G.; Ramos, J.; Gibb, D.M. HIV Med., 2004, 5 (Suppl. 2), 61.
3. The Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated online version (April 7, 2005), available at: http://AIDSinfo.nih.gov.
4. Stolk, L.M.; Luers, J.F. Pharm. World. Sci., 2004, 26, 133.
5. Lalezari, J.P.; Henry, K.; O'Hearn, M.; Montaner, J.S.; Piliero, P.J.; Trottier, B.; Walmsey, S.; Cohen, C.; Kuritzkes, D.R.; Eron, J.J.; Ching, J.; DeMasi, R.; Donatacci, L.; Drobnes, C.; Delehanty, J.; Salgo, M. N. Engl. J. Med., 2003, 348, 2175. (The "TORO-1" international multicentre randomized clinical trial).
6. Lazzarin, A.; Clotet, B.; Cooper, D.; Reynes, J.; Arasteh, K.; Nelson, M.; Katlama, C.; Stellbrink, H.J.; Delfraissy, J.F.; Lange, J.; Huson, L.; DeMasi, R.; Wat, C.; Delehanty, J.; Drobnes, C.; Salgo, M. N. Engl. J. Med., 2003, 348, 2186.
7. Clark, R.A.; Wilcox, R.; Besch, C.L. Am. J. Med. Sci., 2004, 328, 10. (exhaustive review on antiretroviral-experienced patients, and all their expected problems).
8. Englund, J.A.; Raskino, C.; Vavro, C.; Palumbo, P.; Ross, L.L.; McKinney, R.; Nikolic-Djokic, D.; Calgrove, R.C.; Baker, C.J. Pediatr. Infect. Dis. J., 2004, 23, 15.
9. Rockstroh, J.K; Mauss, S. J. Antimicrob. Chemother., 2004, 53, 700.
10. Klein, M.B.; Willemot, P.; Murphy, T.; Lalonde, R.G. AIDS, 2004, 18, 1895. (robust analysis on the background and consequences of sequencing antiretroviral agents for an optimal management of HIV disease)
11. Barbaro, G.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C.T. Curr. Pharm. Des., 2005, 11, 1805.
12. Sabbatani, S.; Manfredi, R.; Biagetti, C.; Chiodo, F. Clin. Drug Invest., 2005, 25, 527.
13. Dando, T.M.; Perry, C.M. Drugs, 2003, 63, 2755. (excellent and comprehensive review of the 2003 "state of the art" on enfuvirtide).
14. Hardy, H.; Skolnik, P.R. Pharmacotherapy, 2004, 24, 198. (exhaustive pharmacological appraisal of the characteristics of enfuvirtide, among the developing class of fusion inhibitors).
15. Greenberg, M.; Cammack, N.; Salgo, M.; Smiley, L. Rev. Med. Virol., 2004, 14, 321. (excellent contribution on the role of fusion inhibition and enfuvirtide in the fight against HIV infection).
16. Roche Laboratories Inc., Trimeris Inc. Fuzeon® (enfuvirtide) for injection: complete product information (US). Updated online version available at: http://www.rocheusa.com/products/fuzeon/pi/.pdf.
17. Hasson, H.; Castagna, A,: Clementi, M.; Menzo, S.; Denise, A.; Lazzarin, A. New. Microbiol., 2004, 27 (Suppl. 1), 11. (The "TORO-2" international multicentre randomized clinical trial).
18. Oldfield, V.; Keating, G.M.; Plosker, G. Drugs, 2005, 65, 1139. (the most comprehensive and updated review on all aspects of enfuvirtide use, dated Summer 2005, and containing 107 references selected from an extensive literature selection).
19. Raffi, F. Med. Maladl. Infect., 2004, 34 (Suppl. 1), 3.
20. Liu, S.; Lu, H.; Niu, J.; Xu, Y.; Wu, S.; Jiang, S. J. Biol. Chem., 2005, 280, 11259.
21. Barretina, J.; Blanco, J.; Bonjoch, A.; Llano, A.; Clotet B.; Esté J.A. AIDS,. 2004, 18, 1673. (novel insights into immunological and virological properties of in vivo enfuvirtide use).
22. Hartt, J.K.; Liang, T.; Sahagun-Ruiz, A.; Ming Wang, J.; Liang-Gao, J.; Murphy, P.A. Biochem. Biophys. Res. Commun., 2000, 272, 699.
23. Church, J.A.; Hughes, M.; Chen, J.; Palumbo, P.; Mofenson, L.M.; Delora, P.; Smith, E.; Wiznia, A.; Hawkins, E.; Sista, P.; Cunningham, C.K. Pediatr. Infect. Dis. J., 2004, 23, 713.
24. Clotet, B.; Raffi, F.; Cooper, D.; Delfraissy, J.F.; Lazzarin, A.; Moyle, G.; Rockstroh, J.; Soriano, V.; Schapiro, J. AIDS, 2004, 18, 1137. (updated recommendations of enfuvirtide use by an international expert panel).
25. Ghosn, J.; Chaix, M.L.; Peytavin, G.; Rey, E.; Bresson, J.L.; Goujard, C.; Katlama, C.; Viard, J.P.; Treluyer, J.M.; Rouzioux, C. AIDS, 2004, 18, 1958.
26. Patel, I.H.; Zhang, X.; Nieforth, K.; Salgo, M.; Buss, N. Clin. Pharmacokinet., 2005, 44, 175. (a 2005 update of pharmacokinetic and pharmacodynamic properties of enfuvirtide).
27. Soy, D.; Aweeka, F.T.; Church, J.A.; Cunningham, C.K.; Palumbo, P.; Kosel, B.W.; Scheiner, L.B. Clin. Pharmacol. Ther., 2003, 74, 569. (study of pharmacokinetic parameters of enfuvirtide in children, and their clinical implications).
28. McKinney, R.E. Jr.; Cunningham, C.K. Curr. Opin. Pediatr., 2004, 16, 76.
29. Bellibas, S.E.; Siddique, Z.; Dorr, A.; Bertasso, A.; Sista, P.; Kolis, S.J.; Cotler, S.; Delora, P. Pediatr. Infect. Dis. J., 2004, 23, 1137.
30. Manfredi, R.; Calza, L.; Chiodo, F. Recenti. Progr. Med., 2005, 96, 124.
31. Manfredi, R.; Calza, L.; Chiodo, F. Ital. J. Pediatr., 2005, 31, 130.
32. Crabb, C. AIDS, 2003, 17, N13.
33. Poveda, E.; Rodes, B.; Labernardiére, J.L.; Benito, J.M.; Toro, C.; Gonzalez-Lahoz, J.; Faudon, J.L.; Clavel, F.; Shapiro, J.; Soriano, V. J. Med. Virol., 2004, 74, 21. (complete and well-based review of possible mechanisms of resistance to enfuvirtide, and their eventual clinical implications).
34. Menzo, S.; Castagna, A.; Monachetti, A.; Hasson, H.; Danese, A.; Carini, E.; Bagnarelli, P.; Lazzarin, A.; Clementi, M. Antimicrob. Agents. Chemother., 2004, 48, 3253.
35. Greenberg, M.L.; Cammack, N. J. Antimicrob. Chemother., 2004, 54, 333. (excellent review on mechanisms of resistance to enfuvirtide, and their possible clinical impact).
36. Wei, X.; Decker, J.M.; Liu, H.; Zhang, Z.; Arani, R.B.; Kilby, J.M.; Saag, M.S.; Wu, X.; Shaw, G.M.; Kappes, J.C. Antimicrob. Agents Chemother., 2002, 46, 1896.
37. Sax, P.E.; Losina, E.; Weinstein, M.C.; Paltiel, A.D.; Goldie, S.J.; Muccio, T.M.; Kimmel, A.D.; Zhang, H.; Freedberg, K.A.; Walensky, R.P. J. Acquir. Immune. Defic. Syndr., 2005, 39, 69. (the first published study devoted to a comprehensive pharmacoeconomic appraisal of enfuvirtide in different scenarios).
38. Ferranti, S.; Menichetti, F. N. Engl. J. Med., 2003, 349, 815.
39. Maggi, P.; Ladisa, N.; Cinori, E.; Altobella, A.; Pastore, G.; Filotico, R. J. Antimicrob. Chemother., 2004, 53, 678.
40. Cohen, C.J.; Clumeck, N.; Molina, J.M.; Thompson, M.; Patel, K.; Wintfeld, N.; Green, J. J. Acquir. Immune. Defic. Syndr., 2004, 37, 1140. (first available study devoted to the quality of life appraisal in enfuvirtide-treated patients with advanced HIV disease).